GENINUS Inc. (KOSDAQ:389030)

Market Cap	77.54B
Revenue (ttm)	8.81B
Net Income (ttm)	-12.80B
Shares Out	33.35M
EPS (ttm)	-383.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,164,639
Average Volume	2,140,089
Open	2,120.00
Previous Close	2,090.00
Day's Range	2,120.00 - 2,580.00
52-Week Range	1,080.00 - 2,935.00
Beta	0.99
RSI	66.08
Earnings Date	Nov 14, 2025

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of next generation sequencing (NGS) - based genome analysis solutions in South Korea. It offers CancerSCAN, an NGS-based cancer genome diagnosis solution; LiquidSCAN, a liquid biopsy NGS test; and Celinus, a single-cell analysis solution for ultra-precise genome analysis. The company also provides HealthSCAN, a genetic test service; WithMe, a service that analyzes gut bacteria characteristics related to the risk of chronic diseases; a...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2018
• Employees: 62
• Stock Exchange: KOSDAQ
• Ticker Symbol: 389030

Financial Performance

In 2024, GENINUS's revenue was 6.46 billion, a decrease of -7.35% compared to the previous year's 6.97 billion. Losses were -12.27 billion, 26.7% more than in 2023.